Tag: nasdaq:vtgn

December 2, 2019

Top 10 Stem Cell Companies On The NASDAQ

The global stem cell therapy market is expected to grow at a CAGR of 36.52 percent between 2017 and 2021....
February 13, 2019

VistaGen Therapeutics Receives Notice of Allowance for U.S. Patent for Treatment of Depression with PH10

VistaGen Therapeutics (NASDAQ:VTGN) has announced that the US Patent and Trademark Office (USPTO) has provided a notice of allowance for...
November 29, 2018

VistaGen Therapeutics Receives Hong Kong Patent for Methods of Production for AV-101

VistaGen Therapeutics (NASDAQ:VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with...
October 25, 2018

VistaGen Therapeutics Acquires Worldwide Rights to Develop and Commercialize PH10

VistaGen Therapeutics (NASDAQ:VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system diseases and disorders with high unmet...
October 3, 2018

VistaGen Therapeutics Receives FDA Fast Track Designation for Development of AV-101 as a Non-Opioid Treatment for Neuropathic Pain

VistaGen Therapeutics (NASDAQ:VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with...
September 13, 2018

VistaGen Therapeutics Acquires Worldwide License of Phase 3-Ready CNS Drug Candidate from Pherin Pharmaceuticals

VistaGen Therapeutics (NASDAQ:VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS)...